1209-17
Pharma - Industry News.

The pharmaceutical industry is a major player in the economy. FindADoc will bring you news and developments that will help you to plan and shield your investments.

We are specifically interested in advances in Hepatitis C treatment, in part because there are so much fewer ways  for physicians to stay abreast of the changes. Prior to the Sunshine Act, Healthcare providers were kept fully informed of developments in drug development from lecture programs and symposia. These allowed interaction between specialists that traded patient experience and shaed new information on clinical problems. The pace of drug development, in the case of hepatitis C was painfully slow and doctors found it very easy to keep up. Like all technology, drug devlopment in the second half of this decade has grown exponentially. The need for education in drug development has never been greater.

So, now tell me, Lawmakers and designers of the Sunshine Act - who suffers? Rich doctors, who at the end of a gruelling 15-hour day, during which they are forced to see patients at the rate of one every 15 minutes, they are enticed to Steak dinners with fancy wines at fancy restaurants, instead of warminng-up with their parent-deprived families, cosy chairs and warm beds ? Or patients, who cannot now benefit from the well-informed opinions of these learned intermediaries? 

We will leave it to the reader to decide. However, as best we can, FindADoc will bring you nuggets of information, richly distilled and presented like nouvelle cuisine, in small delicious packages. Just keep coming!! 

************************************************************************************************************************************

HCV Drug Appears Safe in CKD

The direct-acting antiviral drug sofosbuvir (Sovaldi) appeared to be safe and effective for treating hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD), according to an observational study.

After 12 to 24 weeks of treatment with a sofosbuvir-based combination regimen, 81% of patients achieved a sustained virologic response, and their kidney function remained stable, reported researchers led by Meghan Sise, MD, of Massachusetts General Hospital in Boston.

 

********************************************************

U.S Rate of Maternal HCV Infection Nearly Doubles

In the five year period between 2009 and 2014, the rate of HCV infection in pregnant women in the USA increased by 89 percent (MMWR)

 

 *******************************************************

 

Saturated Hepatitis C Market

Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B 

CORK, Ireland, September 11, 2017 - Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II studies with JNJ-4178 will be completed as planned, but there will be no additional development thereafter. This decision was made in light of the increasing availability of a number of highly effective therapies addressing the medical need in hepatitis C.

“Going forward, our hepatitis R&D efforts will focus on chronic hepatitis B, where a high unmet medical need still exists.  Our scientists are energized by this challenge and our research ambition is to achieve a functional cure of hepatitis B which affects over a quarter of a billion people globally,” said Lawrence M. Blatt, Ph.D., Global Therapeutic Area Head, Infectious Disease Therapeutics, Janssen. “At Janssen, we focus our research and development on areas of greatest unmet medical need where we can combine our excellent internal science with the best available external innovation to bring optimized solutions and maximum benefit to patients.”

Janssen pioneered the advancement of the first innovations in hepatitis C for nearly a decade when it co-developed telaprevir, a first-in-class protease inhibitor used in combination therapy for the treatment of chronic hepatitis C virus.1 In collaboration with Medivir AB, Janssen subsequently developed and launched the second generation protease inhibitor OLYSIO® (simeprevir),2 which is approved in countries around the world.

Today, people living with hepatitis C have a much more diverse range of therapies available following a wave of innovative treatments securing approval. For most, the standard of care for hepatitis C therapy has a duration of 8-12 weeks offering a cure to around 92-100% of people treated.3

 

 

 

 

Web Analytics